BTIG raised the firm’s price target on DexCom (DXCM) to $109 from $107 and keeps a Buy rating on the shares after its Q1 results. Revenue topped expectations and a big beat in U.S. sales shows the company is back on track, while its operating expense control offsets gross margin pressures, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: